Through integrated transcriptomics and pharmacological overexpression approaches, we identified the SYK/SH3BP2 signaling pathway as the crucial mechanism driving MASLD pathogenesis. Here, SH3BP2 is linked to metabolic dysfunction-associated steatotic liver disease.